JP2010522564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522564A5 JP2010522564A5 JP2010501176A JP2010501176A JP2010522564A5 JP 2010522564 A5 JP2010522564 A5 JP 2010522564A5 JP 2010501176 A JP2010501176 A JP 2010501176A JP 2010501176 A JP2010501176 A JP 2010501176A JP 2010522564 A5 JP2010522564 A5 JP 2010522564A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- polypeptide
- pharmaceutical composition
- inflammatory
- isolated polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 208000027866 inflammatory disease Diseases 0.000 claims description 20
- 125000000539 amino acid group Chemical group 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 6
- 102000013691 Interleukin-17 Human genes 0.000 claims description 6
- 108050003558 Interleukin-17 Proteins 0.000 claims description 6
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 208000024908 graft versus host disease Diseases 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 208000023504 respiratory system disease Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 208000037487 Endotoxemia Diseases 0.000 claims description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 4
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000007451 chronic bronchitis Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 206010060921 Abdominal abscess Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000005024 Castleman disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010013554 Diverticulum Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 208000034486 Multi-organ failure Diseases 0.000 claims description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 206010038372 Renal arteriosclerosis Diseases 0.000 claims description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010053879 Sepsis syndrome Diseases 0.000 claims description 2
- 206010041660 Splenomegaly Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- 230000010085 airway hyperresponsiveness Effects 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 210000002421 cell wall Anatomy 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 208000007565 gingivitis Diseases 0.000 claims description 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 230000006320 pegylation Effects 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 238000000034 method Methods 0.000 description 15
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/691,000 US20070249533A1 (en) | 2005-09-28 | 2007-03-26 | Il-17a and il-17f antagonists and methods of using the same |
| US90855407P | 2007-03-28 | 2007-03-28 | |
| US98382207P | 2007-10-30 | 2007-10-30 | |
| PCT/US2008/058190 WO2008118930A1 (en) | 2007-03-26 | 2008-03-26 | Soluble il-17ra/rc fusion proteins and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010522564A JP2010522564A (ja) | 2010-07-08 |
| JP2010522564A5 true JP2010522564A5 (enExample) | 2011-04-21 |
Family
ID=39639827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501176A Withdrawn JP2010522564A (ja) | 2007-03-26 | 2008-03-26 | 可溶性ｉｌ−１７ｒａ／ｒｃ融合タンパク質および関連する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7790676B2 (enExample) |
| EP (1) | EP2125880A1 (enExample) |
| JP (1) | JP2010522564A (enExample) |
| KR (1) | KR20100015750A (enExample) |
| CN (1) | CN101679497A (enExample) |
| AU (1) | AU2008230843B2 (enExample) |
| CA (1) | CA2679588A1 (enExample) |
| EA (1) | EA200901154A1 (enExample) |
| IL (1) | IL200808A0 (enExample) |
| MX (1) | MX2009010273A (enExample) |
| WO (1) | WO2008118930A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1765865A2 (en) * | 2004-06-10 | 2007-03-28 | ZymoGenetics, Inc. | Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| CA2679588A1 (en) | 2007-03-26 | 2008-10-02 | Zymogenetics, Inc. | Soluble il-17ra/rc fusion proteins and related methods |
| BRPI0908312A2 (pt) | 2008-05-05 | 2015-08-18 | Novimmune Sa | '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular'' |
| EP2385839B1 (en) | 2009-01-09 | 2014-11-26 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of corneal disorders |
| US8911722B2 (en) | 2009-09-14 | 2014-12-16 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of yeast-based immunotherapy products and responses |
| WO2011044563A2 (en) | 2009-10-10 | 2011-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Il-17 family cytokine compositions and uses |
| TW201117824A (en) * | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| SI2523688T1 (en) | 2010-01-15 | 2018-03-30 | Kirin-Amgen, Inc. | Formulation of antibodies and therapeutic regimes |
| US20130011413A1 (en) * | 2010-02-03 | 2013-01-10 | The University Of Tokyo | Method and Pharmaceutical Composition for Treatment of Intestinal Disease |
| WO2011141823A2 (en) * | 2010-05-14 | 2011-11-17 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
| US9932403B2 (en) | 2010-05-20 | 2018-04-03 | Ablynx Nv | Biological materials related to HER3 |
| US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
| EP3415528B1 (en) * | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| CN102688504A (zh) * | 2012-06-20 | 2012-09-26 | 中国农业大学 | 一种促进水貂增重的药物组合物 |
| CN102688503A (zh) * | 2012-06-20 | 2012-09-26 | 中国农业大学 | 一种促进狐狸增重的药物组合物 |
| US9862932B2 (en) | 2012-07-24 | 2018-01-09 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| EP2890720B1 (en) | 2012-08-30 | 2019-07-17 | The General Hospital Corporation | Compositions and methods for treating cancer |
| MX359950B (es) | 2012-11-20 | 2018-10-17 | Novartis Ag | Casete de expresión optimizado para expresar un polipéptido con un alto rendimiento. |
| WO2015089280A1 (en) | 2013-12-11 | 2015-06-18 | The General Hospital Corporation | Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors |
| CN107857818A (zh) * | 2017-08-07 | 2018-03-30 | 上海科新生物技术股份有限公司 | 一种针对IL‑17和TNF‑α的双特异性融合蛋白 |
| WO2019216422A1 (ja) * | 2018-05-10 | 2019-11-14 | 学校法人東京理科大学 | 制御性Ｔ細胞増加剤、クロストリジウム・クラスターＸＩＶａ菌の増殖促進剤、及び炎症性又はアレルギー性の疾患又は症状の予防、治療、又は改善のための組成物 |
| CN116751277A (zh) * | 2023-01-10 | 2023-09-15 | 武汉爱博泰克生物科技有限公司 | 利用毕赤酵母表达活性重组人il-17a蛋白的方法 |
| JP2026508960A (ja) * | 2023-03-17 | 2026-03-13 | クロジェン・テクノロジー・カンパニー・リミテッド | 自己免疫疾患治療用新規融合タンパク質 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5684032A (en) | 1994-12-13 | 1997-11-04 | Smithkline Beecham Corporation | Compounds |
| ES2229264T5 (es) * | 1995-03-23 | 2009-12-17 | Immunex Corporation | Receptor il-17. |
| US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
| US20030100051A1 (en) | 1998-05-12 | 2003-05-29 | Ruben Steven M. | 97 human secreted proteins |
| US6569645B2 (en) | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US6579520B2 (en) | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
| US20020177188A1 (en) | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| WO1998049307A1 (en) | 1997-05-01 | 1998-11-05 | Zymogenetics, Inc. | Mammalian cytokine-like receptor |
| US5965704A (en) | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
| EP1015488B1 (en) | 1997-09-17 | 2009-09-09 | Human Genome Sciences, Inc. | Interleukin-17 receptor-like protein |
| US7160985B2 (en) | 1997-10-29 | 2007-01-09 | Genentech, Inc. | Pro180 polypeptide |
| US20030040471A1 (en) | 1998-04-29 | 2003-02-27 | Watson James D. | Compositions isolated from skin cells and methods for their use |
| US7247442B1 (en) | 1998-05-12 | 2007-07-24 | Human Genome Sciences, Inc. | Antibodies to HHPEN62 polypeptide |
| US20020182673A1 (en) | 1998-05-15 | 2002-12-05 | Genentech, Inc. | IL-17 homologous polypedies and therapeutic uses thereof |
| ES2292242T5 (es) | 1998-05-15 | 2011-05-04 | Genentech, Inc. | Utilizaciones terapéuticas de polipéptidos homólogos de il-17. |
| US20030166132A1 (en) | 1998-08-26 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030009013A1 (en) | 1998-12-30 | 2003-01-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7507404B2 (en) | 1999-03-08 | 2009-03-24 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030199041A1 (en) | 1999-07-07 | 2003-10-23 | Presnell Scott R. | Interleukin-17 receptor homologue |
| DE60034564T2 (de) | 1999-07-07 | 2007-12-27 | Zymogenetics, Inc., Seattle | Menschlicher cytokinrezeptor |
| ES2333772T3 (es) | 1999-12-23 | 2010-03-01 | Genentech, Inc. | Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas. |
| US20040048249A1 (en) | 2000-01-21 | 2004-03-11 | Tang Y. Tom | Novel nucleic acids and secreted polypeptides |
| AU2001247306A1 (en) | 2000-03-08 | 2001-09-17 | Human Genome Sciences, Inc. | Immune system-related polynucleotides, polypeptides, and antibodies |
| US20030203451A1 (en) * | 2000-08-24 | 2003-10-30 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US20040197306A1 (en) * | 2000-05-24 | 2004-10-07 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
| US20030092881A1 (en) | 2000-05-24 | 2003-05-15 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
| US20020146763A1 (en) | 2000-07-06 | 2002-10-10 | Zeren Gao | Murine cytokine receptor |
| WO2002038764A2 (en) | 2000-11-10 | 2002-05-16 | The Regents Of The University Of California | Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US20030073623A1 (en) | 2001-07-30 | 2003-04-17 | Drmanac Radoje T. | Novel nucleic acid sequences obtained from various cDNA libraries |
| US6681210B2 (en) | 2001-09-04 | 2004-01-20 | Andrew Jeffrey Kelly | Modular service payroll system |
| US20040097447A1 (en) | 2002-11-16 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of interleukin 22 receptor expression |
| DK1641822T3 (da) | 2003-07-08 | 2013-07-22 | Genentech Inc | Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf. |
| EP1765865A2 (en) | 2004-06-10 | 2007-03-28 | ZymoGenetics, Inc. | Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
| BRPI0616589A2 (pt) | 2005-09-28 | 2011-06-28 | Zymogenetics Inc | polipeptìdeo, e, métodos para produzir um anticorpo para um polipeptìdeo, para reduzir ou inibir a inflamação e para tratar um mamìfero afligido com uma doença inflamatória |
| US20070249533A1 (en) | 2005-09-28 | 2007-10-25 | Levin Steven D | Il-17a and il-17f antagonists and methods of using the same |
| WO2008039553A1 (en) | 2006-02-10 | 2008-04-03 | Zymogenetics, Inc. | Soluble il-17rcx4 and methods of using in inflammation |
| CA2679588A1 (en) | 2007-03-26 | 2008-10-02 | Zymogenetics, Inc. | Soluble il-17ra/rc fusion proteins and related methods |
-
2008
- 2008-03-26 CA CA002679588A patent/CA2679588A1/en not_active Abandoned
- 2008-03-26 US US12/055,597 patent/US7790676B2/en active Active
- 2008-03-26 KR KR1020097021934A patent/KR20100015750A/ko not_active Withdrawn
- 2008-03-26 EP EP08744349A patent/EP2125880A1/en not_active Withdrawn
- 2008-03-26 JP JP2010501176A patent/JP2010522564A/ja not_active Withdrawn
- 2008-03-26 EA EA200901154A patent/EA200901154A1/ru unknown
- 2008-03-26 WO PCT/US2008/058190 patent/WO2008118930A1/en not_active Ceased
- 2008-03-26 MX MX2009010273A patent/MX2009010273A/es not_active Application Discontinuation
- 2008-03-26 CN CN200880017391A patent/CN101679497A/zh active Pending
- 2008-03-26 AU AU2008230843A patent/AU2008230843B2/en not_active Expired - Fee Related
-
2009
- 2009-09-08 IL IL200808A patent/IL200808A0/en unknown
-
2010
- 2010-06-30 US US12/828,041 patent/US8084231B2/en active Active
-
2011
- 2011-11-10 US US13/293,384 patent/US8242072B2/en active Active
-
2012
- 2012-06-04 US US13/487,828 patent/US20120289684A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008509227A5 (enExample) | ||
| JP2009526084A5 (enExample) | ||
| JP2015520169A5 (enExample) | ||
| US9828336B2 (en) | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists | |
| Abe et al. | Sequence of cDNAs encoding actin depolymerizing factor and cofilin of embryonic chicken skeletal muscle: two functionally distinct actin-regulatory proteins exhibit high structural homology | |
| US20080154045A1 (en) | Process for Producing 1-Substituted-3-Fluoroalkylpyrazole-4-Carboxylate | |
| JP2009534297A5 (enExample) | ||
| IL245001B (en) | Antibodies specific to cancer necrosis factor-like ligand 1a and preparations and their uses | |
| JP2010505418A5 (enExample) | ||
| IL314885A (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
| CN114957472B (zh) | 抗IL-4Rα的单域抗体以及应用和药物 | |
| JP2010220614A5 (enExample) | ||
| WO2007111714A3 (en) | Il-21 antagonists | |
| WO2016170545A1 (en) | Process for the preparation of 1-[(3r)-3-[4-amino-3-(4-phenoxyphenvl)-1h- pvrazolo[3,4-d]pyriniidin-1-y1]-1-piperidinvl]-2-propen-1-one and its polymorphs thereof | |
| JP7189211B2 (ja) | 血清中のタンパク質の半減期を増加させるための組成物及び方法 | |
| EP1709046A1 (en) | P38 kinase inhibitors | |
| EP3342783B1 (en) | Method for controlling affinity of antibody for antigen, antibody whose affinity for antigen has been altered, and its production method | |
| US11236325B2 (en) | Methods for nucleic acid capture | |
| JP2022060392A (ja) | 抗体の抗原に対する親和性を制御する方法、抗原に対する親和性が改変された抗体及びその製造方法 | |
| RU2014118966A (ru) | Способ получения изоксазолил-метокси-никотиновых кислот | |
| CN120187445A (zh) | 用于治疗炎症和自身免疫性疾病的方法和组合物 | |
| CN108290818B (zh) | 非对称链状碳酸酯的制造方法 | |
| EP2344532A1 (en) | Purification process for fragment antibodies | |
| CN116143926B (zh) | 一种抗IL1RAcP的单域抗体及其用途 | |
| JP2024530990A5 (enExample) |